Literature DB >> 27984337

Inhibition of osteo/chondrogenic transformation of vascular smooth muscle cells by MgCl2 via calcium-sensing receptor.

Ioana Alesutan1, Rashad Tuffaha, Tilman Auer, Martina Feger, Burkert Pieske, Florian Lang, Jakob Voelkl.   

Abstract

OBJECTIVES: The progression of vascular calcification, an active process promoted by osteo/chondrogenic transformation of vascular smooth muscle cells (VSMCs) is attenuated by activation of the calcium-sensing receptor (CASR). Recent in-vitro studies revealed that vascular calcification could be blunted by Mg, but the underlying mechanisms remained elusive. The present study explored whether the effects of MgCl2 on vascular calcification involve the CASR.
METHODS: Experiments were performed in primary human aortic smooth muscle cells (HAoSMCs) and in the mouse vascular calcification model of vitamin D3 overload.
RESULTS: Phosphate-induced calcium deposition and mRNA expression of the osteogenic markers msh homeobox 2 (MSX2), CBFA1 (core-binding factor α 1), and ALPL (tissue-nonspecific alkaline phosphatase) in HAoSMCs were blunted by additional treatment with MgCl2. MgCl2 upregulated CASR mRNA expression in HAoSMCs in a dose-dependent manner. Furthermore, the inhibitory effects of MgCl2 on phosphate-induced calcium deposition and osteogenic markers mRNA expression were mimicked by the CASR agonist GdCl3 and reversed by additional treatment with the CASR antagonist NPS-2143 or by silencing of the CASR gene in HAoSMCs. MgCl2 also blunted the osteogenic transformation of VSMCs induced by hydroxyapatite particles. High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. These effects were paralleled by increased aortic Casr mRNA expression in cholecalciferol-treated mice, which was further augmented by MgCl2.
CONCLUSION: The protective effects of MgCl2 on osteo/chondrogenic transformation of VSMCs and vascular calcification involve regulation of CASR and CASR-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27984337     DOI: 10.1097/HJH.0000000000001202

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

1.  SGK1 induces vascular smooth muscle cell calcification through NF-κB signaling.

Authors:  Jakob Voelkl; Trang Td Luong; Rashad Tuffaha; Katharina Musculus; Tilman Auer; Xiaoming Lian; Christoph Daniel; Daniel Zickler; Beate Boehme; Michael Sacherer; Bernhard Metzler; Dietmar Kuhl; Maik Gollasch; Kerstin Amann; Dominik N Müller; Burkert Pieske; Florian Lang; Ioana Alesutan
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

2.  Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-κB.

Authors:  Jakob Voelkl; Rashad Tuffaha; Trang T D Luong; Daniel Zickler; Jaber Masyout; Martina Feger; Nicolas Verheyen; Florian Blaschke; Makoto Kuro-O; Andreas Tomaschitz; Stefan Pilz; Andreas Pasch; Kai-Uwe Eckardt; Juergen E Scherberich; Florian Lang; Burkert Pieske; Ioana Alesutan
Journal:  J Am Soc Nephrol       Date:  2018-04-13       Impact factor: 10.121

3.  Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.

Authors:  Joost P Schanstra; Trang Td Luong; Manousos Makridakis; Sophie Van Linthout; Vasiliki Lygirou; Agnieszka Latosinska; Ioana Alesutan; Beate Boehme; Nadeshda Schelski; Dirk Von Lewinski; William Mullen; Stuart Nicklin; Christian Delles; Guylène Feuillet; Colette Denis; Florian Lang; Burkert Pieske; Jean-Loup Bascands; Harald Mischak; Jean-Sebastien Saulnier-Blache; Jakob Voelkl; Antonia Vlahou; Julie Klein
Journal:  JCI Insight       Date:  2019-05-16

Review 4.  Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis.

Authors:  Giuseppe Vezzoli; Lorenza Macrina; Giulia Magni; Teresa Arcidiacono
Journal:  Urolithiasis       Date:  2018-11-16       Impact factor: 3.436

5.  The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.

Authors:  Iain Bressendorff; Ditte Hansen; Morten Schou; Charlotte Kragelund; Lisbet Brandi
Journal:  BMJ Open       Date:  2017-06-23       Impact factor: 2.692

6.  Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes.

Authors:  Christina M Gant; Sabita S Soedamah-Muthu; S Heleen Binnenmars; Stephan J L Bakker; Gerjan Navis; Gozewijn D Laverman
Journal:  Nutrients       Date:  2018-03-05       Impact factor: 5.717

Review 7.  Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.

Authors:  Florian Lang; Christina Leibrock; Lisann Pelzl; Meinrad Gawaz; Burkert Pieske; Ioana Alesutan; Jakob Voelkl
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-04       Impact factor: 5.555

8.  Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation.

Authors:  Anique D Ter Braake; Paul T Tinnemans; Catherine M Shanahan; Joost G J Hoenderop; Jeroen H F de Baaij
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

9.  Impact of β-glycerophosphate on the bioenergetic profile of vascular smooth muscle cells.

Authors:  Ioana Alesutan; Franco Moritz; Tatjana Haider; Sun Shouxuan; Can Gollmann-Tepeköylü; Johannes Holfeld; Burkert Pieske; Florian Lang; Kai-Uwe Eckardt; Silke Sophie Heinzmann; Jakob Voelkl
Journal:  J Mol Med (Berl)       Date:  2020-06-02       Impact factor: 4.599

10.  SGK1-dependent stimulation of vascular smooth muscle cell osteo-/chondrogenic transdifferentiation by interleukin-18.

Authors:  Nadeshda Schelski; Trang T D Luong; Florian Lang; Burkert Pieske; Jakob Voelkl; Ioana Alesutan
Journal:  Pflugers Arch       Date:  2019-01-31       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.